The standard of care for Canadians with Gaucher disease just changed. The drug costs per patient per year will be reduced by about $100,000 and it is all due to the pan-Canadian Pharmaceutical Agency (pCPA).
Anyone who has participated in the Canadian healthcare system understands that it is complicated. And like many endeavours, the more government agencies involved, the more complicated (and convoluted) it seems to get. The same is true for the approval and disbursement of new medicines.